cobas EGFR Mutation Test v2

Somatic Gene Mutation Detection System

FDA Premarket Approval P120019 S016

This medical device record is a pma supplement. A supplement may have changed the device description/function or indication from that approved in the original pma. Be sure to look at the original pma record for more information.

Pre-market Approval Supplement Details

Approval of the cobas® egfr mutation test v2. The device is a real-time pcr test for the qualitative detection of defined mutations of the epidermal growth factor receptor (egfr) gene in non-small cell lung cancer (nsclc) patients. Defined egfr mutations are detected using dna isolated from formalin-fixed paraffin-embedded tumor tissue (ffpet) or circulating-free tumor dna (cfdna) from plasma derived from edta anti-coagulated peripheral whole blood. The test is indicated as a companion diagnostic to aid in selecting nsclc patients for treatment with the targeted therapies listed in table 1 below in accordance with the approved therapeutic product labeling:table 1drug ffpet plasmatarceva® (erlotinib) exon 19 deletions and l858r exon 19 deletions and l858rtagrisso® (osimertinib) exon 19 deletions, l858r, and t790m t790m*patients with positive cobas® egfr mutation test v2 test results using plasma specimens for the presence of the egfr mutations listed above are eligible for treatment with the corresponding drug as indicated in table 1 (see note* for t790m). Patients who are negative for these mutations by this test using plasma specimens should be reflexed to routine biopsy and testing for egfr mutations with the ffpet sample type. *the efficacy of tagrisso (osimertinib) has not been established in the egfr t790m plasma-positive, tissue-negative or unknown population and clinical data for t790m plasma-positive patients are limited; therefore testing using plasma specimens is most appropriate for consideration in patients from whom a tumor biopsy cannot be obtained. Drug safety and efficacy have not been established for the following egfr mutations also detected by the cobas® egfr mutation test v2. Table 2drug ffpet plasmatarceva® (erlotinib) g719x, exon 20 insertions, t790m, s768i, and l861q g719x, exon 20 insertions, t790m, s768i, and l861qtagrisso® (osimertinib) g719x, exon 20 insertions, s768i, and l861q g719x, exon 19 deletions, l858r, exon 20 insertions, s768i, and l861qfor manual sample preparation, ffpet specimens are processed using the cobas® dna sample preparation kit and plasma specimens are processed using the cobas® cfdna sample preparation kit. The cobas z 480 analyzer is used for automated amplification and detection.

Devicecobas EGFR Mutation Test v2
Classification NameSomatic Gene Mutation Detection System
Generic NameSomatic Gene Mutation Detection System
ApplicantROCHE
Date Received2017-10-27
Decision Date2018-04-18
PMAP120019
SupplementS016
Product CodeOWD
Advisory CommitteePathology
Supplement TypeNormal 180 Day Track
Supplement ReasonLabeling Change - Indications/instructions/shelf Life/tradename
Expedited ReviewNo
Combination Product No
Applicant Address ROCHE 4300 Hacienda Drive po Box 9002 pleasanton, CA 94588

Supplemental Filings

Supplement NumberDateSupplement Type
P120019Original Filing
S034 2022-10-21 30-day Notice
S033
S032 2020-07-27 30-day Notice
S031
S030 2019-09-20 30-day Notice
S029 2019-06-27 Real-time Process
S028 2019-04-24 30-day Notice
S027
S026 2018-11-13 30-day Notice
S025 2018-11-09 30-day Notice
S024 2018-08-21 30-day Notice
S023 2018-07-27 30-day Notice
S022 2018-06-08 30-day Notice
S021 2018-06-04 30-day Notice
S020 2018-03-01 30-day Notice
S019 2018-02-23 Normal 180 Day Track
S018 2017-11-30 Normal 180 Day Track
S017 2017-10-30 30-day Notice
S016 2017-10-27 Normal 180 Day Track
S015 2017-09-26 30-day Notice
S014 2017-07-17 30-day Notice
S013 2017-07-14 30-day Notice
S012 2016-09-22 30-day Notice
S011 2016-08-22 30-day Notice
S010 2016-07-08 30-day Notice
S009 2016-04-18 30-day Notice
S008 2015-06-24 30-day Notice
S007 2015-05-28 Panel Track
S006 2015-03-13 30-day Notice
S005 2014-12-19 30-day Notice
S004 2013-12-13 Real-time Process
S003 2013-08-14 30-day Notice
S002 2013-08-09 30-day Notice
S001 2013-07-26 30-day Notice

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.